Absci (ABSI) Share-based Compensation (2020 - 2026)
Absci's (ABSI) quarterly Share-based Compensation came in at $4.4 million in Q1 2026, down 10.85% year-on-year from $4.9 million in Q1 2025, and up 2.89% quarter-over-quarter from $4.3 million in Q4 2025.
Absci (ABSI) Share-based Compensation (2020 - 2026) Analysis & Trends
Absci has disclosed Share-based Compensation across 7 years of filings, most recently posting $4.4 million for Q1 2026.
- Share-based Compensation for Q1 2026 came in at $4.4 million, down 10.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.8 million (down 14.38% YoY), and the FY2025 annual result was $18.3 million, down 5.81% from the prior year.
- Share-based Compensation came in at $4.4 million for Q1 2026 at Absci, up from $4.3 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $5.5 million in Q3 2024 to a low of $1.0 million in Q4 2022.
- The 5-year median for Share-based Compensation is $4.2 million (2022), against an average of $3.9 million.
- Across the five-year window, Share-based Compensation slumped 68.32% in 2022 and surged 210.45% in 2023, its largest moves.
- Absci's Share-based Compensation stood at $1.0 million in 2022, then soared by 210.45% to $3.2 million in 2023, then surged by 59.42% to $5.1 million in 2024, then declined by 16.0% to $4.3 million in 2025, then grew by 2.89% to $4.4 million in 2026.
- The last three Share-based Compensation figures came in at $4.4 million (Q1 2026), $4.3 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Absci | 1.13 Bn | 1.01 Bn | - | 4.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.38 Mn |
| Mar 31, 2026 | 4.38 Mn |
| Dec 31, 2025 | 4.26 Mn |
| Dec 31, 2025 | 4.26 Mn |
| Sep 30, 2025 | 4.40 Mn |
| Sep 30, 2025 | 4.40 Mn |
| Jun 30, 2025 | 4.75 Mn |
| Jun 30, 2025 | 4.75 Mn |
| Mar 31, 2025 | 4.91 Mn |
| Mar 31, 2025 | 4.91 Mn |
| Dec 31, 2024 | 5.07 Mn |
| Dec 31, 2024 | 5.07 Mn |
| Sep 30, 2024 | 5.51 Mn |
| Sep 30, 2024 | 5.51 Mn |
| Jun 30, 2024 | 5.29 Mn |
| Jun 30, 2024 | 5.29 Mn |
| Mar 31, 2024 | 3.59 Mn |
| Mar 31, 2024 | 3.59 Mn |
| Dec 31, 2023 | 3.18 Mn |
| Dec 31, 2023 | 3.18 Mn |